| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 19.1 | 15.9 |
| Gross profit | 3.1 | 2.3 |
| Net income | -2.3 | -1.8 |
| EPS (diluted, $ a share) | $-0.59 | $-0.49 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +20.1% |
|---|---|
| Gross margin | 16.3% |
| Operating margin | -11.6% |
10-Q filed with the SEC, NASDAQ: RMTI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Rockwell Medical, Inc.: key numbers
- Share price
- $6.76Close, Nov 16
- Market cap
- $27.2M
- Shares outstanding
- 4.03MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Rockwell Medical, Inc.
All →Rockwell Medical Financial Results
Rockwell Medical reported third quarter 2026 net sales of $19.1 million, a 20% increase year-over-year, driven by higher volumes from existing and new customers. The company highlighted its pending transformational acquisition of Vantive's hemodialysis business, which is projected to generate annual revenue between $400 million and $450 million.
- Term
- Q3 2026
“We have maintained solid upward momentum across our business, driven by robust market demand and disciplined execution. Our third quarter 2026 net sales grew 20% year-over-year, reflecting strong customer adoption and market validation of our products.”
Mark Strobeck, Ph.D., President and Chief Executive Officer
Rockwell Medical Signs $125M M&A Deal with Vantive Limited
Rockwell Medical has entered into a definitive agreement to acquire Vantive Limited's global in-center hemodialysis business for a base purchase price of $125 million. The acquisition includes manufacturing facilities in Italy, operations in 35 jurisdictions, and a product portfolio spanning concentrates, machines, and water treatment systems. The deal is expected to transform Rockwell into a global provider with projected annual revenues between $400 million and $450 million.
- Value
- $125M
- Counterparty
- Vantive Limited
“Acquiring Vantive’s hemodialysis assets and associated operations represents a transformative step in Rockwell Medical’s evolution and directly advances the strategy we have been executing over the past several years.”
Mark Strobeck, Ph.D., President and Chief Executive Officer at Rockwell Medical